Effect of dimethyl-β-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5176-5185

  Jalalipour, Monireh ^a   Najafabadi, Abdolhossien Rouholamini ^a,b   Gilani, Kambiz ^a   Esmaily, Hadi ^a   Tajerzadeh, Hosnieh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Dimethyl cyclodextrin; Dry powder inhaler; Fine particle fraction; Pulmonary absorption; Recombinant human growth hormone

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; HUMAN GROWTH HORMONE; LACTOSE; PHARMATOSE 325 M; POLYSORBATE; POLYSORBATE 20; UNCLASSIFIED DRUG; ZINC;

AEROSOL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRY POWDER; GEL PERMEATION CHROMATOGRAPHY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN AGGREGATION; RAT; SPRAY DRYING;

EID: 57349198332     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21353     Document Type: Article

References (40)

1. Jorgensen JOL. 1991. Human growth hormone replacement therapy: Pharmacological and clinical aspects. Endocr Rev 12:189-207.
2. Vance ML, Mauras N. 1999. Growth hormone therapy in adults and children. N Engl J Med 341:1206-1216.
3. Dalboge H, Madsen B, Jorgenson KD, Carlson S. 1988. Assessment of risks in connection with use of a recombinant E. Coli strain for production of human growth hormone. Dan Med Bull 35:84-91.
4. Daugherty AL, Liggitt HD, McCabe JG, Moorr JA, Patton JS. 1988. Absorption of recombinant methionyl-human growth hormone (Met-hGH) for rat nasal mucosa. Int J Pharm 45:197-206.
5. Lee HJ, Riley G, Johnson O, Cleland JL, Kim N, Charnis M, Bailey L, Duenas E, Shahzamani A, Marian M, Jones AJS, Putney SD. 1997. In vivo characterization of sustained-release formulations of human growth hormone. J Pharm Exp Ther 281:1431-1439.
6. Bosquillon C, Préate V, Vanbever R. 2004. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 96:233-244.
7. Colthorpe P, Farr SJ, Smith IJ, Wyatt D, Taylor G. 1995. The influence of regional deposition on the pharmacokinetics of pulmonary delivered human growth hormone in rabbits. Pharm Res 12:356-359.
8. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. 2001. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2:198-209.
9. Yu J, Chien YW. 1997. Pulmonary drug delivery: Physiological and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 14:395-453.
10. Adjei AL, Gupta PK. 1997. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker. pp. 151-231.
11. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. 1992. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm 88:63-73.
12. Colthorpe P, Farr SJ, Taylor G, Smith IJ, Wyatt D. 1992. The pharmacokinetics of pulmonary delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit. Pharm Res 9:764-768.
13. Niven RW, Lott FD, Ip AY, Cribbs JM. 1994. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colonystimulating factor (rhG-CSF) to the rabbit. Pharm Res 11:1101-1109.
14. Niven R, editor. 1997. Dry powder formulations for inhalation. Adv Drug Deliv Rev. 26: 1-67.
15. Yamamoto A, Umemori S, Muranishi S. 1994. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and the protease inhibitors in rats. J Pharm Pharmacol 46:14-18.
16. Todo H, Okamoto H, Iida K, Danjo K. 2001. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 220:101-110.
17. Szejtli J. 1988. Cyclodextrin technology. Dordrecht, Boston, London: Kluwer academic publishers. pp. 1-450.
18. Irie T, Uekama K. 1999. Cyclodextrins in peptide and protein delivery. Adv Drug Del Rev 36:101-123.
19. Shimpi S, Chauhan B, Shimpi P. 2005. Cyclodextrins: Application in different routes of drug administration. Acta Pharm 55:139-156.
20. Shao ZJ, Mitra AK. 1996. Pulmonary absorption of recombinant human growth hormone in rats. Eur J Pharm Biopharm 42:199-203.
21. Hussain A, Yang T, Zaghloul A-A, Ahsan F. 2003. Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β- cyclodextrin. Pharm Res 20:1551-1557.
22. Shao Z, Li Y, Mitra AK. 1994. Cyclodextrins as mucosal absorption promoters of insulin, III. Pulmonary route of delivery. Eur J Pharm Biopharm 40:283-288.
23. Shao Z, Krishnamoorthy R, Mitra AK. 1992. Cyclodextrins as nasal absorption promoters of insulin: Mechanistic evaluations. Pharm Res 9:1157-1163.
24. Ohtani Y, Irie T, Uekama K, Fukunaga K, Pitha J. 1989. Differential effects α-, β- and γ-cyclodextrins on human erythrocytes. Eur J Biochem 186:17-22.
25. Maa Y-F, Nguyen P-A, Hsu S. 1998. Spray-drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci 87:152-159.
26. Jalalipour M, Gilani K, Tajerzadeh H, Rouholamini Najafabadi A, Barghi M. 2007. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int J Pharm (in press).
27. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. 2004. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 21:2369-2376.
28. Pearlman R, Beweley TA. 1993. Stability and characterization of human growth hormone. In: Wang YJ, Pearlman R, editors. Stability and characterization of protein and peptide drugs: Case histories. New York: Plenum Press. pp. 1-58.
29. Zeng XM, Martin GP, Marriott C, Pritchard J. 2001. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J Pharm Sci 90:1424-1434.
30. Enna SJ, Schanker LS. 1972. Absorption of saccharides and urea from the rat lung. Am J Physiol 222:409-414.
31. Okamoto H, Aoki M, Danjo K. 2000. A novel apparatus for rat in vivo evaluation for dry powder formulations for pulmonary administration. J Pharm Sci 89:1028-1035.
32. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
33. Charman SA, Mason KL, Charman WN. 1993. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res 10:954-962.
34. Maa Y-F, Costantino HR, Nguyen PA, Hsu CC. 1997. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol 2:213-223.
35. Johnson KA. 1997. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 26:3-15.
36. Zeng XM,Martin GP, Marriott C. 2001. Particle interactions in dry powder formulations for inhalation. 1st edition. London: Taylor and Francis. pp. 123-128.
37. French DL, Edwards DA, Niven RW. 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27:769-783.
38. Nambu N, Shimoda M, Takahashi Y, Ueda H, Nagai T. 1978. Bioavailability of powdered inclusion compounds of nonsteroidal anti-inflammatory drugs with b-cyclodextrin in rabbits and dogs. Chem Pharm Bull 26:2952-2956.
39. Merkus FWHM, Verhoef JC, Romeijn SG, Schipper NGM. 1991. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588-592.
40. Hussain A, Arnold JJ, Khan MA, Ahsan F. 2004. Absorption enhancers in pulmonary protein delivery. J Control Release 94:15-24.